103 possessing a Ser195Ala mutation relative to wild-type PR3-Val
INTRODUCTION
Proteinase 3 (PR3) is a neutrophil serine protease targeted by antineutrophil cytoplasmic antibodies (ANCAs) in the autoimmune disease granulomatosis with polyangiitis (GPA) (1) (2) (3) (4) (5) . To investigate how PR3 interacts with the ANCAs during inflammation and whether these interactions can be intervened by therapeutics, we developed a human PR3 mutant (iPR3-Val
103

MATERIAL AND METHODS
Materials
Reagents were obtained from Sigma (St. Louis, MO) unless specified otherwise. The human epithelial kidney cell line 293 used for the expression of recombinant PR3 mutants was obtained from ATCC (Rockville, MD).
iPR3-Val
103 and iHm5-Val
103
: The cDNA constructs coding for iPR3-Val 103 and iHm5-Val 103 and their expression in HEK293 cells were described in detail elsewhere (11, 13) . Both mutants carry a carboxyterminal cmyc-peptide extension and a poly-His peptide extension for purification using nickel columns from GE Healthcare (Chicago, IL) and for anchoring in ELISAs as previously described and specified below (11, (13) (14) (15) (16) .
moANCA518: DNA barcode-enabled sequencing of the antibody repertoire was performed on plasmablasts derived from a PR3-targeting ANCA (PR3-ANCA) positive patient as described for rheumatoid arthritis and Sjögren syndrome elsewhere (17, 18) . Phylograms of the antibody repertoires revealed clonal families of affinity matured antibodies with shared heavy and light chain VJ usage.
Twenty-five antibodies were selected for recombinant expression (17) and tested for reactivity with recombinant ANCA antigens (including myeloperoxidase (16) , human neutrophil elastase (19-21),
iPR3-Val
103
, and iHm5-Val
) using the ELISA. One antibody bound iHm5-Val 103 but not iPR3-Val 103 as described in Results and is termed moANCA518, whereas none of the other 24 antibodies bound either of the two PR3 antigens or other ANCA antigens.
Epitope-specific anti-PR3 moAbs: PR3G-2 (22) was a gift from C.G.M. Kallenberg. WGM2 (11, 23 ) was purchased from Hycult Biotech Inc (Wayne, PA). MCPR3-3 (8, 11) was made as previously described.
Enzyme-linked immunosorbent assays
ELISAs used for detection of PR3-ANCA were described in detail elsewhere (13, 14, 16) . In brief, either purified PR3 mutants or culture media supernatants from PR3 mutant expressing 293 cell clones diluted in the IRMA buffer (0.05 mM Tris-HCl, 0.1 M NaCl, pH 7.4, and 0.1% bovine serum albumin) were incubated in Pierce® nickel-coated plates from Thermo Fisher Scientific (Waltham, CA) for 1 hour at room temperature; control wells were incubated with the IRMA buffer only. The plates were washed three times with Tris-buffered saline (TBS; 20 mM Tris-HCl, 500 mM NaCl, pH 7.5, and 0.05% Tween 20) in between steps. The ANCA-containing serum samples were diluted 1:20
in TBS with 0.5% bovine serum albumin and incubated in the plates with or without the PR3 mutants for 1 hour at room temperature. The PR3•ANCA complexation was detected after incubation for 1 hour at room temperature with alkaline phosphatase-conjugated goat anti-human IgG (1:10,000 dilution). P-Nitrophenyl phosphate was used as substrate at a concentration of 1 mg/mL. The net UV absorbance was obtained by spectrophotometry at 405 nm after 30 minutes of exposure. Similarly, when epitope-specific anti-PR3 moAbs were used to immobilize iHm5-Val 103 on Maxisorp® plates from Invitrogen (Carlsbad, CA), complexation of moANCA518 with the antigen was detected after incubation of HRP-conjugated anti-human IgG antibody (1:250 dilution) for 1 hour at room temperature; 3,3',5,5'-tetramethylbenzidine (Thermo Fisher Scientific®) was used as substrate, and the net UV absorbance was obtained by spectrophotometry at 450 nm after 15 minutes of exposure.
Western blots
Non-reductive, purified PR3 mutant proteins were loaded (1 µg/lane) onto 12% Tris-HCl gels from BioRad (Hercules, CA). The SDS gel electrophoresis was performed at 180 volts for 35 minutes. The proteins were transferred from gels to nitrocellulose membranes, which were subsequently washed with TBS, blocked for 45 minutes at room temperature with TBS with 0.2% non-fat dry milk. The membranes were then washed twice with TBS with 0.1% Tween 20. Monoclonal antibodies (0.5-1.0 µg/mL) were incubated on the membranes overnight at 4 °C. 
Initial conformations of PR3 variants
The initial conformation of PR3-Ile 103 (residues 16-239; truncated for atomic charge neutrality) was taken from the crystal structure of PR3 (24 conformations. The AMBER residue names of ASP, GLU, ARG, LYS, HID, and CYX were used for all Asp, Glu, Arg, Lys, His, and Cys residues, respectively. All initial conformations were refined via energy minimization using the SANDER module of AMBER 11 (University of California, San Francisco) and forcefield FF12MClm (25) with a dielectric constant of 1.0, a cutoff of 30.0 Å for nonbonded interactions, and 200 cycles of steepest descent minimization followed by 100 cycles of conjugate gradient minimization.
Molecular dynamics simulations
Each of the four energy-minimized conformations described above was solvated with 5578 (for iHm5- 
Alpha carbon B-factor calculation
In a two-step procedure using PTRAJ of AmberTools 1.5, the B-factors of alpha carbon (Cα) atoms in PR3 were calculated from all conformations saved at every 10 3 timesteps during 20 simulations of the protein using the simulation conditions described above except that (i) the atomic masses of the entire simulation system (both solute and solvent) were uniformly increased by 100-fold relative to the standard atomic masses, (ii) the simulation temperature was lowered to 300 K, and (iii) the simulation time was reduced to 500 ps. The first step was to align all saved conformations onto the first saved conformation to obtain an average conformation using the root mean square fit of all Cα atoms. The second step was to perform root mean square fitting of all Cα atoms in all saved conformations onto the corresponding atoms of the average conformation. The Cα B-factors were then calculated using the "atomicfluct" command in PTRAJ. For each protein, the calculated B-factor of any atom in Table S2 
Conformational cluster analysis and root mean square deviation calculation
The conformational cluster analyses were performed using CPPTRAJ of AmberTools 16 with the average-linkage algorithm (34), epsilon of 3.0 Å, and root mean square coordinate deviation on all Cα atoms of the proteins (Table S1 ). Cα root mean square deviations (CαRMSDs) were manually calculated using ProFit V2.6 (http://www.bioinf.org.uk/software/profit/). The first unit of the crystal structure of the PR3 tetramer and the average conformation (without energy minimization) of the most populated cluster were used for the CαRMSD calculation.
RESULTS
In characterizing moAbs identified and cloned from B cells in patients with GPA, we found that one of these, moANCA518, bound to iHm5-Val 103 but not iPR3-Val 103 ( (11). These models were derived from MD simulations using our published forcefield and simulation protocol (25), which reportedly folded fast-folding proteins in isobaric-isothermal MD simulations to achieve agreements between simulated and experimental folding times within factors of 0.69-1.75 (35) and are hence suitable for predicting in vivo conformations of PR3 and its variants.
The initial conformations of the three variants used in these simulations were derived from the PR3- Table S1 ). Given these conformational properties, we could not determine how mutations of these variants affect the ANCA-binding capabilities of the PR3 epitopes, primarily because these surface loops are highly flexible and lack the time dimension that is required for immunological function analysis (36).
To take the time dimension into account, we turned our attention to the dynamic properties of (Figure 3) .
Consistent with the two seminal reports (38, 39), all of these potentially antigenic loops identified a priori by using simulated B-factors fall within all four known epitopes of PR3 (11), demonstrating a clear association between a loop with a high mean simulated Cα B-factor and the experimentally determined antigenicity of the loop.
Further, we found that the Ser195Ala mutation caused no significant reduction in the mean Cα B-factor of any of the 10 potentially antigenic surface loops in PR3-Val 103 ( Figure 3A) . Figure 3B) . According to the afore-described antigenicity criterion of 9.00 Å 2 , these means suggest that the three chimeric mutations make Loop 3B (a mutation-free loop) more mobile in iHm5-Val
103
, despite large separations between Epitope 3 of PR3 and the chimeric mutation sites (~32 Å, ~32 Å, and ~31 Å from the Cα atom of Gln122 in Epitope 3 to the Cα atoms of Ala146, Trp218, and Leu223, respectively, at the chimeric mutation sites). Therefore, We subsequently repeated the afore-described ELISAs in the presence of epitope-specific moAbs that target either Epitope 1 or 3 of PR3. Consistently, we found that PR3G-2 that targets Epitope 1 of PR3 (22) did not affect the binding of moANCA518 to iHm5-Val
, whereas MCPR3-3 and WGM2, both of which recognize Epitope 3 of PR3 (11), reduced and abolished the moANCA518 binding (p < 0.01; Figure 2B ), respectively. We also confirmed the binding of moANCA518 primarily to Epitope 3
DISCUSSION
In view of the data above, we suggest a new mechanism for epitope activation of PR3: Remote mutations can increase the local mobility (i.e., main-chain flexibility) of a latent epitope of PR3, which facilitates the conformational adaptation required for antibody binding and thereby activate the latent epitope. In the same vein, it is plausible that the binding of MCPR3-7 to PR3 modulates the mainchain flexibility of a topographically remote site of PR3, which contributes to the reported allosteric inhibition of PR3 by . This type of exquisite epitope activation or inhibition-achieved either in vitro by remote mutations as we demonstrated or in vivo conceivably by remote protein•protein interactions or remote polymorphisms-may be a fundamental feature of GPA.
It is worth noting that identifying PR3 mutations in patients with GPA that can increase the 
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